BIIB

As of 2026-09-11, BIIB scores 50out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. BIIB trades at $215.43, 5% below the band floor.

BIIB scores 50 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 50. Its strongest factor is value at 76 (strong), where it screens cheap on the model's valuation inputs, followed by momentum at 52. The weakest is quality at 40, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 25% of the Healthcare names the model scores.

On valuation, BIIB is priced near the floor of its own recent range — the cheap end on the model's valuation read. The blended composite before the macro overlay was 52. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on BIIB, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where BIIB sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for BIIB runs $226.28–$326.23. Current price $215.43 sits 5% below the band floor. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.